ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit www.prokidney.com.
| Website | http://www.prokidney.com |
| Ticker | PROK |
| Revenue | $154 million |
| Employees | 239 (185 on RocketReach) |
| Address | 2000 Frontis Plaza Blvd 250, Winston-Salem, North Carolina 27103, US |
| Phone | +1 336-999-7028 |
| Industry | Biotechnology Research, Business Services General, Business Services |
| Keywords | Chronic Kidney Disease Treatment, Cellular Therapy, Kidney Disease Treatment, Regenerative Medicine, Autologous Cell Therapy, Kidney Failure Treatment, End Stage Renal Disease Treatment, Esrd Treatment |
| Competitors | Pfizer, Johnson & Johnson, Merck & Co., Inc., Novartis, Lilly India, Bristol Myers Squibb, Roche, Amgen, Gilead Sciences, Regeneron +43 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 541 Companies |
Looking for a particular ProKidney Corp. employee's phone or email?
The ProKidney Corp. annual revenue was $154 million in 2026.
Bruce Culleton is the CEO of ProKidney Corp..
185 people are employed at ProKidney Corp..
ProKidney Corp. is based in Winston-Salem, North Carolina.
The NAICS codes for ProKidney Corp. are [54, 541].
The SIC codes for ProKidney Corp. are [873, 87].